Please login to the form below
difficult-to-treat cancers
This page shows the latest difficult-to-treat cancers news and features for those working in and with pharma, biotech and healthcare.
Regeneron set to acquire Checkmate for approximately $250m
a promising new modality to Regeneron's toolkit of potential approaches for difficult-to-treat cancers. ... We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family.".
Latest news
-
Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA
The site, situated in the US, is set to produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancers. ... strengthen our ability to meet the needs of people living with difficult-to-treat blood cancers,” said Christi Shaw, CEO of Kite.
-
Cancer Research UK and Teon Therapeutics announce treatment of first patient in phase 1/2 trial for difficult-to-treat cancers
dosed adenosine receptor antagonist, TT-702, for the treatment of patients with a range of difficult-to-treat cancers. ... treat cancers, which is why we are so delighted that we have successfully advanced TT-702 into human trials with Teon, safely
-
Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
advanced or recurrent disease have limited options available to them once the disease progresses following platinum-based chemotherapy. ... The phase 3 Study 309/KEYNOTE-775 trial demonstrates the ongoing commitment that Eisai and Merck share in
-
Gilead to pay $745m for three oncology programmes from Arcus Biosciences
deliver benefit to patients with some of the most difficult to treat cancers, including pancreatic, lung, colon and prostate.”. ... Gilead will also pay Arcus tiered royalties ranging from ‘the mid-teens to the low twenties’.
-
GSK/Merck KGgA cancer drug fails in third trial
This bifunctional approach is thought to control tumour growth by potentially restoring and enhancing anti-tumour responses. ... In preclinical studies, bintrafusp alfa demonstrated activity both as a monotherapy and in combination with chemotherapy,
More from news
Approximately 1 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
Amgen Oncology, one of the leading developers of innovative therapies for novel targets in difficult-to-treat cancers, is working to bring new hope for transforming clinical outcomes for patients with ... Visit AmgenOncology.com to learn more about the
-
A snapshot of Crescendo Biologics
What is the central focus of Crescendo’s research? The company is focused on T-cell enhancement to develop new ways to treat difficult cancer types. ... success – or to make advances in those cancers that are still difficult to treat in this way.
-
Radiosurgery innovation
Radiosurgery has greatest application in patients with difficult-to-treat cancers such as brain tumours. ... This was a tough ask of Pegasus as our technology is highly complex and it can be difficult to get journalists to understand its potential, let
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- My journey advancing the science in pulmonary hypertension
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
Fishawack Health
Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
